(Nature Medicine 2024)
Looks like we are really progressing to clinical validation ... (see also https://www.agingconsortium.org/)
Moqri M, Herzog C, Poganik JR, et al. Validation of biomarkers of aging. Nat Med. Published online February 14, 2024.
https://pubmed.ncbi....h.gov/38355974/
"The search for biomarkers that quantify biological aging (particularly 'omic'-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials."
"...We anticipate that the ideal biomarkers of aging shall have moderate
to strong associations with chronological age and predict multiple
aging-related outcomes beyond mortality, such as functional decline,
frailty, chronic diseases and disability and (multi)morbidity. They
should be sensitive to upstream factors thought to influence aging
such as stress, adverse events, environment, genetics and lifestyle, and
they should mediate the relationship between these factors and aging
outcomes. They should do so in many diverse populations and should
do so relatively similarly across populations. Biomarkers of aging that
meet these requirements should be prioritized for validation as screening
and diagnostic biomarkers and eventually as surrogate endpoints
in clinical trials..."
Screenshot 2024-02-17 235503.png 261.24KB
0 downloads
See also the prior work published in Cell, sort of preparation to the work for Nat. Med. above:
Moqri M, Herzog C, Poganik JR, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023;186(18):3758-3775.
https://pubmed.ncbi....h.gov/37657418/
"With the rapid expansion of aging biology research, the identification and evaluation of longevity interventions in humans have become key goals of this field. Biomarkers of aging are critically important tools in achieving these objectives over realistic time frames. However, the current lack of standards and consensus on the properties of a reliable aging biomarker hinders their further development and validation for clinical applications. Here, we advance a framework for the terminology and characterization of biomarkers of aging, including classification and potential clinical use cases. We discuss validation steps and highlight ongoing challenges as potential areas in need of future research. This framework sets the stage for the development of valid biomarkers of aging and their ultimate utilization in clinical trials and practice."
